Innovative Therapeutics in Oncology and Neuroscience
2
Forward-Looking Statements
This presentation contains forward-looking statements relating to our strategy and plans; potential of and expectations for our business and pipeline
programs; our goals and expectations under our growth strategy (including our expectations regarding our commercial-stage products, clinical-stage
global-right products, revenue growth / CAGR, profitability and timeline to profitability, operating margins, and cash flow); the peak sales potential of our
programs; capital allocation and investment strategy; clinical development programs and related clinical trials; clinical trial data, data readouts, and
presentations; risks and uncertainties associated with drug development, commercialization and outreach; regulatory discussions, submissions, filings,
and approvals and the timing thereof; the potential benefits, safety, and efficacy of our products and product candidates and those of our collaboration
partners; the expected benefits and potential of investments, collaborations, and business development activities; our future financial and operating
results; and financial guidance. All statements, other than statements of historical fact, included in this presentation are forward-looking statements, and
can be identified by words such as "aim," "anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend," "may," "plan,"
"possible," "potential," "target," "will," "would," and other similar expressions. Such statements constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees or assurances of future performance.
Forward-looking statements are based on our expectations and assumptions as of the date of this presentation and are subject to inherent uncertainties,
risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ
materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to
successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives,
(3) the results of clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory
authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors discussed in our
most recent annual and quarterly reports and other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that
subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any
forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. These forward-looking
statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation.
Our SEC filings can be found on our website at www.zailaboratory.com and on the SEC's website at http://www.sec.gov.
This presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities of Zai Lab Limited.
zaiLabView entire presentation